title: Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: in vitro and in vivo studies.
abstract: Growth inhibition of murine and human myeloid leukemia cells by differentiation inducers during long-term culture was examined to improve the strategy for therapy of myeloid leukemia by differentiation inducers. When the effect of 1 alpha,25-dihydroxyvitamin D3, a typical differentiation inducer, on proliferation of mouse myeloid leukemia M1 cells was examined at a constant product of time and concentration (480 nM in 20 days), the continuous treatment with 24 nM 1 alpha,25-dihydroxyvitamin D3 was the most effective for inhibition of cell proliferation. After 20 days, the cumulative cell number was reduced about 3 X 10(5) times by continuous treatment with 24 nM 1 alpha,25-dihydroxyvitamin D3. Similar results were obtained when M1 cells were treated continuously with dexamethasone. M1 cells resistant to 1 alpha,25-dihydroxyvitamin D3 appeared about 25 days after the start of continuous treatment with 24 nM 1 alpha,25-dihydroxyvitamin D3. On the other hand, when M1 cells were treated continuously with 1 alpha,25-dihydroxyvitamin D3 and noncytotoxic doses of antileukemic drugs such as 1-beta-D-arabinofuranosylcytosine and daunomycin, resistant cells did not appear for at least 35 days. A similar effect of 1 alpha,25-dihydroxyvitamin D3 and antileukemic drugs on cell proliferation was observed with the human monoblast-like cell line U937. The survival of syngeneic SL mice inoculated with M1 cells was prolonged more by treatment with both 1 alpha-hydroxyvitamin D3 and daunomycin than by treatment with either drug alone. These results suggest that continuous treatment with both differentiation inducers and certain antileukemic drugs may be more effective therapeutically than treatment with a differentiation inducer alone.
authors.forename: T
authors.initials: T
authors.lastname: Kasukabe
authors.forename: Y
authors.initials: Y
authors.lastname: Honma
authors.forename: M
authors.initials: M
authors.lastname: Hozumi
authors.forename: T
authors.initials: T
authors.lastname: Suda
authors.forename: Y
authors.initials: Y
authors.lastname: Nishii
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D002117:Calcitriol / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage*; D003907:Dexamethasone / Q000494:pharmacology; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D007942:Leukemia, Experimental / Q000188:drug therapy* / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D013997:Time Factors
chemical_list: D006887:Hydroxycholecalciferols; D003561:Cytarabine; D003609:Dactinomycin; D003907:Dexamethasone; D002117:Calcitriol; D003630:Daunorubicin